D iagnostic, therapeutic, and investigative efforts in multiple sclerosis have concentrated on disease of the white matter. Imaging and histopathological studies suggest that cortical damage is a correlate of cognitive dysfunction and disease progression, reflecting demyelination or secondary neurodegeneration. [1] [2] [3] [4] [5] [6] [7] Three types of cortical plaques have been described: leukocortical lesions, which extend from the white matter into the cortex; intracortical lesions, which project radially from microvessels; and subpial lesions, which extend intracortically from the pia mater. 5, 8 Subpial, bandlike, demyelinated plaques often involve contiguous gyri, 6 favoring those regions of the brain engaged in attention and memory processing. 6, 8, 9 Studies of postmortem tissues from patients with long-standing multiple sclerosis have led to the suggestion that cortical demyelination contributes to disability in patients with progressive multiple sclerosis, 6 occurs independently of whitematter lesions, 6 is driven by organized meningeal inflammatory infiltrates 10, 11 and is devoid of parenchymal lymphocytes and macrophages, 4, 5, 8 suggesting that neurodegeneration proceeds independently of parenchymal inflammation.
Little is known about cortical demyelination in early multiple sclerosis because conventional magnetic resonance imaging (MRI) does not reveal most lesions. Double inversion-recovery imaging (not routinely performed in practice) detects some but not all cortical lesions. Other neuroimaging studies in early multiple sclerosis have revealed varied, nonlesional cortical abnormalities, [12] [13] [14] suggesting that the cortex may be damaged near the time of disease onset -a concept further supported by recent case reports of cortical-onset multiple sclerosis. 15, 16 Here we report the prevalence, histopathological features, and clinical correlates of cortical demyelination in a series of 563 patients with pathologically confirmed inflammatory demyelinating disease of the central nervous system, diagnosed by means of brain biopsy performed within days or weeks after presentation, to rule out diseases other than multiple sclerosis.
Me thods

Study Design and Series
This study was approved by the institutional review board of the Mayo Clinic. Brain-biopsy specimens were obtained within the context of routine clinical care, with written or oral consent to this surgical procedure obtained by the treating physicians. At the time of study entry, we obtained written informed consent from patients who underwent prospective blood sampling, underwent follow-up MRI, participated in a face-to-face encounter, were interviewed by telephone, or underwent a combination of these assessments. In the case of deceased patients, written informed consent was obtained from the next of kin. The institutional review board issued a waiver of the requirement of consent for the examination of archival pathological material when attempts to contact the patient had been exhausted; samples evaluated under this waiver were deidentified.
Inclusion criteria were a pathological diagnosis of inflammatory demyelinating disease consistent with multiple sclerosis and a sufficient amount of tissue for analyses (≥1 mm 2 ). Exclusion criteria were the presence of acute disseminated encephalomyelitis, 17 neuromyelitis optica, 18 or any other disease of the central nervous system. Clinical information was obtained from patients, family members, or physicians; a review of the patient's medical record; face-to-face encounters; or a combination of these sources. Patients received the diagnosis of multiple sclerosis according to the McDonald 19 or Poser 20 criteria. A single episode indicated a clinically isolated syndrome.
Neuropathological Evaluation
Formalin-fixed, paraffin-embedded sections were stained with hematoxylin and eosin, Luxol fast blue and periodic acid-Schiff, and Bielschowsky silver impregnation. Avidin-biotin immunohistochemical analysis was performed 21 with the use of primary antibodies 22 (see the Supplementary Appendix, available with the full text of this article at NEJM.org). Cortical plaque types were classified according to standard criteria, 4, 5, 8 and demyelinating activity was staged according to published criteria. 23 Grading of cortical inflammation and meningeal inflammation is described in the Supplementary Appendix.
statistical analysis
Statistical inference was made on the basis of logistic-regression analysis, and the strengths of associations were expressed as odds ratios along with 95% confidence intervals. Additional details are provided in the Supplementary Appendix. Figure 1 in the Supplementary Appendix shows the study design. Of the 138 patients for whom a sufficient amount of cortex was available for analysis, 53 (38%) had cortical demyelination. Of the 85 patients without cortical demyelination, 12 (14%) had cortical inflammation and 73 (86%) had cortex that appeared to be normal. All three types of plaque were observed in those with cortical demyelination (Fig. 1A, 1B , and 1C, and Fig.  2A in the Supplementary Appendix). Of 104 lesions studied, leukocortical lesions were the most common (52 [50%]), followed by subpial lesions (35 [34%] ) and intracortical lesions (17 [16%] ). Some single biopsy specimens contained more than one type of plaque (Fig. 1D ).
Clinical Characteristics
Biopsies were typically performed at the time of presentation, with a median interval from symptom onset to biopsy of 27 days (interquartile range, 14 to 72). The median time to biopsy was 26 days (interquartile range, 13 to 73) for the group with cortical demyelination and 44 days (interquartile range, 15 to 64) for the group without cortical demyelination (area under the curve, 0.56; P = 0.59). Of the 138 patients, 77 (56%) underwent comprehensive clinical follow-up (median, 3.5 years; interquartile range, 1.3 to 7.5); multiple sclerosis was diagnosed in 58 of these patients (75%), and a clinically isolated syndrome was diagnosed in 19 (25%). Table 1 in the Supplementary Appendix shows the percentages of patients with and those without cortical demyelination according to diagnosis, which were not significantly different (P = 0.60 by Fisher's exact test). Table 2 in the Supplementary Appendix shows the percentage of patients with cortical demyelination according to follow-up group (Fig. 1 in the Supplementary Appendix). Among those with definite multiple sclerosis or a clinically isolated syndrome, the prevalence of cortical demyelination was 40%, as compared with 38% in the total cohort.
Demyelinating Activity
Cortical lesions in late-stage multiple sclerosis show few actively demyelinating plaques, 4, 5, 8 precluding temporal associations between demyelination and phagocytic macrophages. Lesions were staged according to the presence or absence of myelin debris (indicating active or inactive demyelination, respectively) within macrophages in a subset of cortical lesions (78 lesions from 41 patients) with sufficient tissue for analysis and with a cortical-plaque distribution that was similar to the distribution in the overall cohort. Of these 41 patients, 27 (66%) had cortical lesions that contained foamy macrophages, indicating ongoing demyelination. (We observed 39 active lesions.) Myelin-laden macrophages were found only in the context of cortical demyelination, in all three cortical plaque types ( Fig. 2A) , and most commonly in leukocortical lesions (25 of 39 lesions). Subpial lesions (4 of 26) and intracortical lesions (3 of 13) also contained myelin-laden macrophages (Fig. 3A) , occasionally found in cortical layer 1 at the subpial rim ( Fig. 3B ) and in the subarachnoid space (Fig. 3C ). We detected activated microglia in all 78 cortical lesions.
Cortical Inflammation
In 38 patients who had a representative corticalplaque distribution and sufficient tissue available for analysis, we analyzed 71 cortical lesions for CD3+ T cells and 70 for CD8+ T cells. Perivascular CD3+ T-cell inflammation was observed in 58 of 71 cortical plaques (82%) (Fig. 2B, 3D , and 3E), and CD8+ T cells were present in 54 of 70 cortical plaques (77%) (Fig. 3F , and Fig. 2B in the Supplementary Appendix). Leukocortical lesions were highly inflammatory. The majority of intracortical and subpial plaques contained perivascular CD3+ and CD8+ T-cell infiltrates. Furthermore, 23% of subpial lesions contained moderate-tomarked CD3+ T-cell inflammation. We observed B-cell perivascular cortical inflammation in 4 of 15 cortical plaques analyzed (27%). Owing to limited tissue availability, we did not probe for the presence of other lymphocyte subsets.
Meningeal Inflammation
Of the 138 patients with inflammatory demyelinating disease and with cortical tissue available for analysis, 43 (31%) had meningeal tissue available for analysis. Of these 43 patients, 15 (35%) had cortical demyelination -a proportion similar to that in the overall cohort (38%). Tissue specimens from 2 patients were initially excluded from the analysis because of surgical hemorrhage. We assessed the other 41 patients for focal perivascular meningeal inflammation. Surgical hemorrhage impaired the assessment for diffuse meningeal inflammation in 11 patients, who were then also ex- cluded from the analysis. The patients with cortical demyelination were more likely to have diffuse meningeal inflammation (Table 3 and Fig. 3A in the Supplementary Appendix), as well as moderate or marked focal perivascular meningeal inflammation (Table 4 and Fig. 3B in the Supplementary Appendix), than were the patients without cortical demyelination. Diffuse meningeal inflammation ( Fig. 4A and 4B ) was significantly and strongly associated with cortical demyelination (odds ratio, 45; 95% confidence interval [CI], 4 to 478; P<0.001), whereas focal perivascular meningeal inflammation (Fig. 4C, 4E , and 4F) was less strongly, albeit still significantly, associated with cortical demyelination (odds ratio, 15; 95% CI, 1 to 213; P = 0.002). Among confirmed cases of multiple sclerosis or a clinically isolated syndrome, robust associations between meningeal inflammation and cortical demyelination were noted (Tables 5 through 8 in the Supplementary Appendix). Remarkably, there was a 90% probability that moderate-to-marked meningeal inflammation was topographically associated with cortical demyelination, especially for subpial plaques as compared with intracortical plaques and with leukocortical plaques (P = 0.004 for both comparisons) with respect to diffuse meningeal inflammation, and as compared with intracortical plaques (P = 0.001) and leukocortical plaques (P = 0.03) with respect to focal meningeal inflammation (Fig. 4C) . The time from the onset of symptoms to biopsy was not related to the presence or absence of cortical demyelination or meningeal inflammation.
Neurodegeneration
Neurodegeneration that occurs in multiple sclerosis lesions includes neuronal, neuritic, and oligodendroglial injury, in addition to demyelination. Such changes in the absence of inflammation have been reported in chronic cortical plaques, raising the question of whether inflammation and neurodegeneration are independent processes in multiple sclerosis. 4, 7, 24 Several cortical lesions that we examined showed neuritic swelling, suggesting acute injury, although the majority showed relative preservation of neurites. We observed severe focal neuritic loss in two subpial lesions (one in each of two patients). In one patient, a large focal meningeal infiltrate was topographically associated with a destructive subpial lesion (Fig. 4D) . Oligodendrocyte density was reduced (Fig. 5B ) in a subset of lesions, as compared with adjacent, nondemyelinated cortex (Fig. 5A ). Focal neuronal injury was apparent in several early cortical plaques (Fig. 5C ).
Neurodegenerative changes occurred on a background of inflammation ( Fig. 5D and 5E ).
Discussion
We characterized demyelinating lesions in corticalbiopsy specimens from patients with early-stage multiple sclerosis, which were obtained in passing during diagnostic procedures targeting whitematter lesions (Fig. 4 in the Supplementary Appendix). Nearly 40% of these patients had cortical demyelination. Indirect evidence that cortical demyelination is common in early-stage multiple sclerosis comes from MRI studies showing cortical lesions in approximately 30% of 119 patients with a clinically isolated syndrome. 25 Others have reported cortical lesions and cortical atrophy on MRI in patients with early multiple sclerosis, 26-29 although cortical lesions were not observed in a study of children with multiple sclerosis. 30 The spatial separation of intracortical and subpial lesions (which together represented about 50% of the lesions detected) from the biopsy specimens of white-matter lesions suggests intrinsic cortical demyelinating disease. The prevalence of intrinsic cortical lesions was remarkably high, given the small tissue samples available for study (core diameter, 1 mm).
We do not believe that the presence of tumefactive white-matter lesions affects the biology of the cortical lesions, hence our interpretation of the presence and appearance of these cortical lesions. We believe that the patients in our study who underwent biopsy are typical of those with multiple sclerosis; among 77 patients for whom long-term clinical follow-up data were available, 58 (75%) had definite multiple sclerosis and 19 (25%) were categorized as having a clinically isolated syndrome at the last follow-up.
Understanding the neuropathophysiology of multiple sclerosis requires analysis of tissue, which carries potential biases. Despite atypical clinical and radiographic presentations, evidence suggests that the results of biopsy studies in multiple sclerosis can be cautiously extrapolated to prototypical multiple sclerosis. In a previous study, we compared our patients with a population-based cohort of 218 persons with definite multiple scle- those of patients in the prevalence cohort, who did not undergo biopsy. In another report, multiple sclerosis had developed by the time of the last follow-up assessment (median, 3.9 years) in 70% of 168 patients with tumefactive inflammatory demyelinating disease who underwent biopsy. 32 The relevance of cortical injury in the diagnosis and prognosis of multiple sclerosis is widely ac- knowledged. 28, 33 Cognitive impairment correlates positively with gray-matter atrophy, 34 corticallesion burden, 29 and reduced cortical thickness. 35 Cortical-lesion volume is an independent predictor of disability progression at follow-up, 35 and cortical lesions are less common in patients with benign multiple sclerosis, in which remission between relapses is almost complete, with little (if any) accumulation of disability 15 to 20 years after the diagnosis. 36 Cortical lesions are more common in patients who have relapsing-remitting multiple sclerosis with seizures than in those who have relapsing-remitting multiple sclerosis without seizures. 37 Therefore, an understanding of the prevalence and extent of cortical demyelination in early multiple sclerosis may help inform assessment of the prognosis and treatment decisions.
We found that cortical demyelination is common early in multiple sclerosis, and our characterization of the lesion underscored its inflammatory character. Cortical demyelination that occurs close to the onset of multiple sclerosis differs substantially from that seen in chronic multiple sclerosis. These findings do not support a primary (noninflammatory) neurodegenerative process during early-stage multiple sclerosis. Differences between cortical demyelination in early multiple sclerosis and in long-standing, progressive multiple sclerosis, in which inflammatory cortical demyelination is typically not observed, may relate to efficient clearance of cortical inflammation. 38, 39 With respect to a potential mechanism of disease progression, we speculate that myelin-laden macrophages may leave the cortex, enter the cerebrospinal fluid (CSF), gain access to deep cervical lymph nodes to promote epitope spreading, 40 and thus propagate the disease process (Fig. 5 in the Supplementary Appendix). Antigen-presenting cells injected into the CSF of rodents were found in deep cervical lymph nodes, 41 and macrophage-containing myelin debris has been observed in the cervical lymph nodes of patients with multiple sclerosis. 42 Meningeal aggregates in the tissues of patients with multiple sclerosis may contribute to cortical demyelination and progression. 6, 11, 43, 44 During the prodrome in experimental autoimmune encephalomyelitis, pathogenic T cells enter the CSF, 45, 46 are restimulated by meningeal antigen-presenting cells, 47 undergo clonal expansion, and produce cytokines, promoting T-cell infiltration across pial vessels, 48 activation of deeper vasculature, 49 parenchymal invasion, and the onset of disease. These mechanisms have been studied mainly in the white matter of the spinal cord in experimental autoimmune encephalomyelitis, adjacent to CSF flow pathways. Cortex is the only common CSF-adjacent tissue obtained on biopsy in the clinical setting, and our findings broadly correspond to observations made in experimental autoimmune encephalomyelitis (Fig. 5 in the Supplementary Appendix). Subpial cortical demyelination showed a strong topographic relation to meningeal inflammation, suggesting that meningeal infiltrates may contribute to early cortical demyelination.
We observed concurrent subpial and leukocortical lesions in individual tissue sections, suggesting that superficial demyelinating disease may contribute to the generation of deeper lesions by means of cytokine diffusion. 41 In support of this hypothesis, a recent analysis of autopsy specimens from patients with progressive multiple sclerosis showed antigen-experienced B-cell clones in meningeal aggregates that were identical to those found in parenchymal perivascular spaces near plaques, as indicated by variable-region sequence alignment. 50 Our findings of microglial activation, neuritic injury, pyknotic neurons, and reduced oligodendrocyte density in patients with early multiple sclerosis are consonant with the findings in patients with progressive multiple sclerosis, 4 underscoring the potential of cortical demyelination to cause irreversible injury, although inflammation may resolve rapidly. The relationship between early cortical demyelination and cognitive impairment, disease progression, and cortical atrophy awaits future research.
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